🚀 VC round data is live in beta, check it out!
aXichem Valuation Multiples
Discover revenue and EBITDA valuation multiples for aXichem and similar public comparables like Sinteza, OrganoClick, Hulytego, Directa Plus and more.
aXichem Overview
About aXichem
aXichem AB develops and delivers nature-identical ingredients of the highest purity. The company offers axiphen-feed used in the breeding of chickens and pigs, Bio-repellents used to repel unwanted biological organisms from installations or areas, and aXivite an alternative to capsaicin.
Founded
1999
HQ
Employees
7
Website
Sectors
Financials (LTM)
EV
$9M
aXichem Financials
aXichem reported last 12-month revenue of $3M and negative EBITDA of ($1M).
In the same LTM period, aXichem generated ($1M) in EBITDA losses and had net loss of ($2M).
Revenue (LTM)
aXichem P&L
In the most recent fiscal year, aXichem reported revenue of $2M and EBITDA of ($1M).
aXichem expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $988K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA | ($1M) | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | (40%) | XXX | (67%) | XXX | XXX | XXX |
| EBIT Margin | (59%) | XXX | (93%) | XXX | XXX | XXX |
| Net Profit | ($2M) | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | (60%) | XXX | (94%) | XXX | XXX | XXX |
| Net Debt | — | — | $179K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
aXichem Stock Performance
aXichem has current market cap of $9M, and enterprise value of $9M.
Market Cap Evolution
aXichem's stock price is $0.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9M | $9M | 1.9% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialaXichem Valuation Multiples
aXichem trades at 3.4x EV/Revenue multiple, and (8.4x) EV/EBITDA.
EV / Revenue (LTM)
aXichem Financial Valuation Multiples
As of April 22, 2026, aXichem has market cap of $9M and EV of $9M.
Equity research analysts estimate aXichem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
aXichem has a P/E ratio of (5.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | (8.4x) | XXX | (6.7x) | XXX | XXX | XXX |
| EV/EBIT | (5.7x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.2x | XXX | XXX | XXX |
| P/E | (5.5x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified aXichem Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
aXichem Margins & Growth Rates
aXichem's revenue in the last 12 month grew by 111%.
aXichem's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
aXichem's rule of 40 is 99% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
aXichem's rule of X is 261% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
aXichem Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 111% | XXX | 105% | XXX | XXX | XXX |
| EBITDA Margin | (40%) | XXX | (67%) | XXX | XXX | XXX |
| EBITDA Growth | (100%) | XXX | (72%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 99% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 261% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 142% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
aXichem Public Comps
See public comps and valuation multiples for other Chemicals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| aXichem | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinteza | XXX | XXX | XXX | XXX | XXX | XXX |
| OrganoClick | XXX | XXX | XXX | XXX | XXX | XXX |
| Hulytego | XXX | XXX | XXX | XXX | XXX | XXX |
| Directa Plus | XXX | XXX | XXX | XXX | XXX | XXX |
| Encres Dubuit | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
aXichem M&A Activity
aXichem acquired XXX companies to date.
Last acquisition by aXichem was on XXXXXXXX, XXXXX. aXichem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by aXichem
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialaXichem Investment Activity
aXichem invested in XXX companies to date.
aXichem made its latest investment on XXXXXXXX, XXXXX. aXichem invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by aXichem
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout aXichem
| When was aXichem founded? | aXichem was founded in 1999. |
| Where is aXichem headquartered? | aXichem is headquartered in Sweden. |
| How many employees does aXichem have? | As of today, aXichem has over 7 employees. |
| Is aXichem publicly listed? | Yes, aXichem is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of aXichem? | aXichem trades under AXIC A ticker. |
| When did aXichem go public? | aXichem went public in 2011. |
| Who are competitors of aXichem? | aXichem main competitors are Sinteza, OrganoClick, Hulytego, Directa Plus. |
| What is the current market cap of aXichem? | aXichem's current market cap is $9M. |
| What is the current revenue of aXichem? | aXichem's last 12 months revenue is $3M. |
| What is the current revenue growth of aXichem? | aXichem revenue growth (NTM/LTM) is 111%. |
| What is the current EV/Revenue multiple of aXichem? | Current revenue multiple of aXichem is 3.4x. |
| Is aXichem profitable? | No, aXichem is not profitable. |
| What is the current EBITDA of aXichem? | aXichem has negative EBITDA and is not profitable. |
| What is aXichem's EBITDA margin? | aXichem's last 12 months EBITDA margin is (40%). |
| What is the current EV/EBITDA multiple of aXichem? | Current EBITDA multiple of aXichem is (8.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.